- Home
- SSBK vs ATYR Comparison
SSBK vs ATYR Comparison
Compare SSBK & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSBK
- ATYR
- Stock Information
- Founded
- SSBK 2007
- ATYR 2005
- Country
- SSBK United States
- ATYR United States
- Employees
- SSBK N/A
- ATYR N/A
- Industry
- SSBK Commercial Banks
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SSBK Finance
- ATYR Health Care
- Exchange
- SSBK Nasdaq
- ATYR Nasdaq
- Market Cap
- SSBK N/A
- ATYR 306.2M
- IPO Year
- SSBK 2021
- ATYR 2015
- Fundamental
- Price
- SSBK $36.37
- ATYR $5.31
- Analyst Decision
- SSBK Buy
- ATYR Strong Buy
- Analyst Count
- SSBK 1
- ATYR 6
- Target Price
- SSBK $36.00
- ATYR $20.20
- AVG Volume (30 Days)
- SSBK 34.0K
- ATYR 3.5M
- Earning Date
- SSBK 07-21-2025
- ATYR 08-12-2025
- Dividend Yield
- SSBK 0.99%
- ATYR N/A
- EPS Growth
- SSBK 6.02
- ATYR N/A
- EPS
- SSBK 3.80
- ATYR N/A
- Revenue
- SSBK $99,026,000.00
- ATYR N/A
- Revenue This Year
- SSBK $19.18
- ATYR $960.85
- Revenue Next Year
- SSBK $7.05
- ATYR $1,283.47
- P/E Ratio
- SSBK $9.57
- ATYR N/A
- Revenue Growth
- SSBK 18.43
- ATYR N/A
- 52 Week Low
- SSBK $25.92
- ATYR $1.48
- 52 Week High
- SSBK $39.16
- ATYR $5.98
- Technical
- Relative Strength Index (RSI)
- SSBK 61.75
- ATYR 57.23
- Support Level
- SSBK $35.46
- ATYR $4.96
- Resistance Level
- SSBK $36.80
- ATYR $5.47
- Average True Range (ATR)
- SSBK 0.58
- ATYR 0.37
- MACD
- SSBK 0.16
- ATYR -0.07
- Stochastic Oscillator
- SSBK 85.17
- ATYR 61.11
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.